Protocols
33 protocol(s) meet the specified criteria
Disease Site: Other
Protocol No.TitleStatus
11-1474AAccountability for Cancer Care through Undoing Racism and Equity (ACCURE)Open
13-2058Internet Tobacco Vendors Youth Purchase SurveyOpen
15-3137 A Feasibility Study of Antineoplastic Drug Exposure among Nursing AssistantsOpen
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
201404139Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHNOpen
A091101Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) –a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckOpen
AMGEN359A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)Open (affiliates only)
AMGEN482A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple MyelomaOpen (affiliates only)
B-701-U21A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After, or are Refractory to Standard TherapyOpen
B2151009Phase 1B Study to Assess the Safety, Tolerbaility, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)Open
CA209-274A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial CarcinomaOpen
CALGB90601-CIRBA Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell CarcinomaOpen (affiliates only)
CCCWFU-60A02HIGH POINT- CCCWFU #60A02 - A Phase II Randomized Placebo Controlled, Double Blinded Trial to Evaluate the Effects of Fruit and Vegetable Extracts on Intermediate Biomarkers in Head and Neck Cancer PatientsOpen (affiliates only)
COG-AALL0331Standard Risk B-precursor Acute Lymphoblastic LeukemiaOpen
EA8141A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial CarcinomaOpen
EMR200647-001A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicationOpen
GU14-182A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial CancerOpen
INCB57643-101A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced MalignanciesOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1529New Approaches to Identifying Malignancy in Cystic Kidney Lesions in Patients with Chronic Kidney DiseaseOpen
LCCC1622A Single Arm Evaluation of False Negative Rate of Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases Open
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
MSKCC-13-074Randomized phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) vs. bleomycin, etoposide and cisplatin (BEP) for patients with previously untreated intermediate- and poor- risk germ cell tumorsOpen
NEOD001-CL002A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) AmyloidosisOpen
NRG-BR003-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast CancerOpen
NRG-GY004A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RTOG1008A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Open
SGN19A-003A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplantOpen
SGN33A-004A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)Open
TEST4A four part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine,or Concurrent BKM120 and Capecitabine and Trastuzumab, in Patients with Metastatic Colon Cancer (Test4)Open
WO30070A Phase Iii, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma Who Are Ineligible For Cisplatin-Based TherapyOpen
X4P-001-RCCBA Phase 1b/2a Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell CarcinomaOpen